Expertise in
18
conditions

Dr. Christine Kay

Ophthalmology
Office
4340 Newberry Rd Ste 202, 
Gainesville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
Office
4340 Newberry Rd Ste 202, 
Gainesville, FL 

Overview

Christine Kay is an Ophthalmologist in Gainesville, Florida. Dr. Kay is highly rated in 18 conditions, according to our data. Her top areas of expertise are Color Blindness, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Florida College Of Medicine

Specialties

Ophthalmology

Licenses

Ophthalmology in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Office
4340 Newberry Rd Ste 202, Gainesville, FL 32607
Other Locations
Office
10238 SW 86th Cir Unit 100, Ocala, FL 34481

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Biological
Study Drugs: 4D-150, Aflibercept
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological, Other
Study Drug: 4D-125
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Clinical and Genetic Characterization of Individuals With Achromatopsia
Clinical and Genetic Characterization of Individuals With Achromatopsia
Enrollment Status: Completed
Publish Date: October 13, 2017
View 6 Less Clinical Trials

45 Total Publications

Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Journal: Ophthalmic genetics
Published: October 19, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Nausheen Khuddus
Ophthalmology
Expertise in
16
conditions
Dr. Nausheen Khuddus
Ophthalmology

Family Focus Eye Care

7120 NW 11th Pl, 
Gainesville, FL 
 (1.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nausheen Khuddus is an Ophthalmologist in Gainesville, Florida. Dr. Khuddus is highly rated in 16 conditions, according to our data. Her top areas of expertise are Strabismus, Esotropia, Amblyopia, and Epicanthal Folds. Dr. Khuddus is currently accepting new patients.

Expertise in
12
conditions
Dr. Nazanin Ebrahimiadib
Ophthalmology
Expertise in
12
conditions
Dr. Nazanin Ebrahimiadib
Ophthalmology

Uf Health Eye Center-The Oaks

6201 W Newberry Rd, 
Gainesville, FL 
 (1.2 miles away)
352-265-2020
Languages Spoken:
English
See accepted insurances

Nazanin Ebrahimiadib is an Ophthalmologist in Gainesville, Florida. Dr. Ebrahimiadib is highly rated in 12 conditions, according to our data. Her top areas of expertise are Uveitis, Scleritis, Retinopathy of Prematurity, Retinal Detachment, and Vitrectomy.

Expertise in
16
conditions
Dr. Gregory Snodgrass
Ophthalmology
Expertise in
16
conditions
Dr. Gregory Snodgrass
Ophthalmology

North Florida Cataract Specialists And Vision Care LLC

4313 NW 8th Ave, 
Gainesville, FL 
 (0.2 miles away)
352-375-0404
Languages Spoken:
English
See accepted insurances

Gregory Snodgrass is an Ophthalmologist in Gainesville, Florida. Dr. Snodgrass is highly rated in 16 conditions, according to our data. His top areas of expertise are Cataract, Macular Corneal Dystrophy Type 1, Corneal Dystrophy and Perceptive Deafness, and Fuchs Dystrophy.

Frequently Asked Questions about Dr. Christine Kay

How do I make an appointment with Dr. Christine Kay?

You can book an appointment with Dr. Christine Kay by calling their office at 352-371-2800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christine Kay a top-rated expert for Color Blindness?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christine Kay is classified as an Elite expert for Color Blindness, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christine Kay specialize in?

While Dr. Christine Kay is a Ophthalmology, they have specific expertise in Color Blindness, Retinitis Pigmentosa, and Retinopathy Pigmentary Mental Retardation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Christine Kay participate in research or clinical trials?

Yes. Dr. Christine Kay has published 45 articles and abstracts on conditions like Color Blindness. You can view a list of Dr. Christine Kay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christine Kay accept my insurance?

Dr. Christine Kay accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 352-371-2800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kay's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile